Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma

Trial Profile

Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma

Discontinued
Phase of Trial: Phase 0

Latest Information Update: 01 Oct 2015

At a glance

  • Drugs BQ 788 (Primary)
  • Indications Malignant melanoma
  • Focus First in man; Proof of concept; Therapeutic Use
  • Sponsors MelCure
  • Most Recent Events

    • 22 May 2015 Status changed from not stated to discontinued.
    • 15 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top